RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE
2015-01-01 Rege-Cambrin, G; Fava, C; Dogliotti, I; Berchialla, P; Gottardi, E; Cerrano, M; Ferrero, D; Nicolosi, M; Pregno, P; Orlandi, E; Cattaneo, D; Iurlo, A; Catania, G; Davide, R; Saglio, G
IMATINIB DISCOTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON 28 UNSELECTED PATIENTS
2014-01-01 Cerrano, M; Fava, C; Pregno, P; Giai, V; Nicolosi, M; Aguzzi, C; Dogliotti, I; Rege-Cambrin, G; Boccadoro, M; Vitolo, U; Saglio, G; Ferrero, D
Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.
2007-01-01 Nitin Jain; Hagop M. Kantarjian; Carmen Fava; Deborah Thomas; Jan A. Burger; Gautam Borthakur; Odeal Pate; and Jorge Cortes.
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?
2011-01-01 Roberto Latagliata; Massimo Breccia; Dario Ferrero; Francesco Cavazzini; Malgorzata Monika Trawinska; Fausto Castagnetti; Mario Annunziata; Fabio Stagno; Mario Tiribelli; Silvia Imbergamo; Carmen Fava; Elena Crisà; Giuseppe Pietrantuono; Antonella Gozzini; Franca Falzetti; Enrico Montefusco; Alessandra Iurlo; Caterina Musolino; Michele Cedrone; Antonella Russo Rossi; Patrizia Pregno; Giuseppe Visani; Isabella Capodanno; Mauro Endri; Antonio Spadea; Gianfranco Giglio; Francesca Celesti; Simona Sica; Sergio Storti; Ada M D'Addosio; Giovanna Rege Cambrin; Luigiana Luciano; Elisabetta Abruzzese; Gianantonio Rosti; and Giuliana Alimena.
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia.
2011-01-01 Carlo Gambacorti-Passerini; Laura Antolini; Rocco Piazza; François Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp D. le Coutre; Rafael Hurtado Monroy; Valeria Santini; Fabrizio Pane; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Francesca Pavesi; Miriam Puttini; Christian Rizzo; Ilaria Dilda; Silvia Mori; Dong-Wook Kim; and Maria Grazia Valsecchi.
Imatinib long-term effects study: global independent assessment of imatinib in chronic myeloid leukemia: results at 7 years.
2011-01-01 Gambacorti-Passerini C; Antolini L; Piazza R; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D’Emilio A; Stagno F; le Coutre P; Monroy FH; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Pavesi F; Cecchetti C; Altieri C; Rizzo C; Dilda I; Mori S; Kim DW; Valsecchi MG.
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
2010-01-01 Tiribelli M; Latagliata R; Breccia M; Luciano L; Castagnetti F; Gozzini A ; Rege Cambrin G; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Sorà F; Ferrero D; Montefusco E; Cavazzini F; Binotto G; Fanin R; Pane F; Rosti G; Santini V; Fava C; Alimena G; Vigneri P
IMPACT OF BCR-ABL1 TRANSCRIPT TYPE IN CHRONIC MYELOID LEUKEMIA TREATED FRONTLINE WITH NILOTINIB
2017-01-01 Castagnetti, F; Gugliotta, G; Breccia, M; Stagno, F; D'Adda, M; Levato, L; Angelucci, E; Martino, B; Tiribelli, M; Fava, C; Binotto, G; Capodanno, I; Bocchia, M; Bergamaschi, M; Russo-Rossi, A; Cavazzini, F; Abruzzese, E; Soverini, S; Foa, R; Cavo, M; Martinelli, G; Saglio, G; Pane, F; Baccarani, M; Rosti, G
Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
2007-01-01 Bruno Martino; Giovanna Rege Cambrin; Antonella Gozzini; Fabio Stagno; Massimo Breccia; Giorgina Specchia; Ester Orlandi; Ester Pungolino; Franca Falzetti; Sara Galimberti; Carmen Fava; Antonio Marino; and Francesco Nobile.
Incidence of Deep Molecular Response and Its Association with Clinical and Molecular Variables in Patients with Chronic Myeloid Leukemia Treated with Imatinib in a Population with Limited Health Resources
2020-01-01 Reyes, BG; Aguilera, CRB; Fava, C; Garcia, EM; Benitez, AVL; Hernandez, TDA; Martinez, LMV; Hernandez, AEG; Rodriguez, AR; Hernandez, JCL; Vazquez, ORG; Mendoza, LAR; Alatorre, AFAG; Valdez, ASC; Pimentel, SMV
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE | 2015 | Rege-Cambrin, G; Fava, C; Dogliotti, I; Berchialla, P; Gottardi, E; Cerrano, M; Ferrero, D; Nicolosi, M; Pregno, P; Orlandi, E; Cattaneo, D; Iurlo, A; Catania, G; Davide, R; Saglio, G | |
| IMATINIB DISCOTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON 28 UNSELECTED PATIENTS | 2014 | Cerrano, M; Fava, C; Pregno, P; Giai, V; Nicolosi, M; Aguzzi, C; Dogliotti, I; Rege-Cambrin, G; Boccadoro, M; Vitolo, U; Saglio, G; Ferrero, D | |
| Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib. | 2007 | Nitin Jain; Hagop M. Kantarjian; Carmen Fava; Deborah Thomas; Jan A. Burger; Gautam Borthakur; Odeal Pate; and Jorge Cortes. | |
| Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? | 2011 | Roberto Latagliata; Massimo Breccia; Dario Ferrero; Francesco Cavazzini; Malgorzata Monika Trawinska; Fausto Castagnetti; Mario Annunziata; Fabio Stagno; Mario Tiribelli; Silvia Imbergamo; Carmen Fava; Elena Crisà; Giuseppe Pietrantuono; Antonella Gozzini; Franca Falzetti; Enrico Montefusco; Alessandra Iurlo; Caterina Musolino; Michele Cedrone; Antonella Russo Rossi; Patrizia Pregno; Giuseppe Visani; Isabella Capodanno; Mauro Endri; Antonio Spadea; Gianfranco Giglio; Francesca Celesti; Simona Sica; Sergio Storti; Ada M D'Addosio; Giovanna Rege Cambrin; Luigiana Luciano; Elisabetta Abruzzese; Gianantonio Rosti; and Giuliana Alimena. | |
| Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia. | 2011 | Carlo Gambacorti-Passerini; Laura Antolini; Rocco Piazza; François Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp D. le Coutre; Rafael Hurtado Monroy; Valeria Santini; Fabrizio Pane; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Francesca Pavesi; Miriam Puttini; Christian Rizzo; Ilaria Dilda; Silvia Mori; Dong-Wook Kim; and Maria Grazia Valsecchi. | |
| Imatinib long-term effects study: global independent assessment of imatinib in chronic myeloid leukemia: results at 7 years. | 2011 | Gambacorti-Passerini C; Antolini L; Piazza R; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D’Emilio A; Stagno F; le Coutre P; Monroy FH; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Pavesi F; Cecchetti C; Altieri C; Rizzo C; Dilda I; Mori S; Kim DW; Valsecchi MG. | |
| IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB | 2010 | Tiribelli M; Latagliata R; Breccia M; Luciano L; Castagnetti F; Gozzini A ; Rege Cambrin G; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Sorà F; Ferrero D; Montefusco E; Cavazzini F; Binotto G; Fanin R; Pane F; Rosti G; Santini V; Fava C; Alimena G; Vigneri P | |
| IMPACT OF BCR-ABL1 TRANSCRIPT TYPE IN CHRONIC MYELOID LEUKEMIA TREATED FRONTLINE WITH NILOTINIB | 2017 | Castagnetti, F; Gugliotta, G; Breccia, M; Stagno, F; D'Adda, M; Levato, L; Angelucci, E; Martino, B; Tiribelli, M; Fava, C; Binotto, G; Capodanno, I; Bocchia, M; Bergamaschi, M; Russo-Rossi, A; Cavazzini, F; Abruzzese, E; Soverini, S; Foa, R; Cavo, M; Martinelli, G; Saglio, G; Pane, F; Baccarani, M; Rosti, G | |
| Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). | 2007 | Bruno Martino; Giovanna Rege Cambrin; Antonella Gozzini; Fabio Stagno; Massimo Breccia; Giorgina Specchia; Ester Orlandi; Ester Pungolino; Franca Falzetti; Sara Galimberti; Carmen Fava; Antonio Marino; and Francesco Nobile. | |
| Incidence of Deep Molecular Response and Its Association with Clinical and Molecular Variables in Patients with Chronic Myeloid Leukemia Treated with Imatinib in a Population with Limited Health Resources | 2020 | Reyes, BG; Aguilera, CRB; Fava, C; Garcia, EM; Benitez, AVL; Hernandez, TDA; Martinez, LMV; Hernandez, AEG; Rodriguez, AR; Hernandez, JCL; Vazquez, ORG; Mendoza, LAR; Alatorre, AFAG; Valdez, ASC; Pimentel, SMV |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 04-CONTRIBUTO IN ATTI DI CONVEGNO 86
- 04-CONTRIBUTO IN ATTI DI CONVEGNO... 86
Data di pubblicazione
- 2010 - 2020 66
- 2005 - 2009 20
Editore
- Amer Soc Hematology 1
Rivista
- BLOOD 44
- HAEMATOLOGICA 36
- CLINICAL LYMPHOMA & MYELOMA 2
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2
- LEUKEMIA RESEARCH 1
- MULTIPLE SCLEROSIS 1
Keyword
- acute lymphoblastic leukemia 1
- ALL 1
- clinical variables 1
- CML 1
- deep molecular response 1
- molecular variables 1
- Philadelphia-positive leukemia 1
- real life 1
- TKI 1
Lingua
- eng 86
Accesso al fulltext
- no fulltext 86